16 completed. 16 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 16 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Omacor: new trials by email Literature Review of Omacor trials Research Report on Omacor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Altering Lipids for Tolerance of Aromatase Inhibitor Therapy Omega-3 fatty acid supplement - Breast Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 77 | 2020-07-28 | 2026-05-06 |
| A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Epanova® (omega-3 carboxylic acids), Omacor® (omega-3-acid ethyl esters) - Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency | Phase 2 | Completed | AstraZeneca | 490 | 2015-03-01 | 2017-01-20 |
| Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention Eicosapentanoic acid and docosahexanoic acid, Oleic Acid - Colorectal Adenomatous Polyps | Phase 2 | Completed | Vanderbilt University | 141 | 2013-02-04 | 2018-06-08 |
| A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia LCQ908, Fenofibrate, Fish Oil - Non Familial Chylocmicronemia Syndrome (Non-FCS) | Phase 2 | Completed | Novartis Pharmaceuticals | 58 | 2012-06-01 | 2020-12-17 |
| Breast Cancer Risk Biomarkers in Premenopausal Women Lovaza™ - Breast Cancer | Phase 2 | Completed | Carol Fabian, MD | 36 | 2010-11-01 | 2016-07-21 |
| Breast Cancer Risk Biomarkers in Postmenopausal Women Lovaza™ - Breast Cancer | Phase 2 | Completed | Carol Fabian, MD | 35 | 2010-11-01 | 2016-12-16 |
| Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g) - Severe Hypertriglyceridemia | Phase 2 | Completed | AstraZeneca | 54 | 2010-09-01 | 2015-07-15 |
| Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia Lovaza - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Sanford Research | 15 | 2009-09-01 | 2021-10-20 |
| Fish Oil Study for High Triglyceride Levels in Children Omega-3-acid ethyl esters, Placebo - Hypertriglyceridemia | Phase 2 / Phase 3 | Completed | Babu Balagopal | 42 | 2009-07-01 | 2022-11-08 |
| Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease Lovaza, Placebo - HIV Infections, Heart Disease | Phase 2 | Completed | University Hospitals Cleveland Medical Center | 35 | 2009-04-01 | 2015-01-07 |
| The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Lovaza (omega-3-acid ethyl esters), Wheat Germ Oil - Muscle Damage, Muscle Inflammation | Phase 2 | Completed | Western Michigan University | 20 | 2009-03-01 | 2012-09-05 |
| The Effects of Omega-3 Fatty Acids on Aspirin Resistance Aspirin, Lovaza, Both Aspirin and Lovaza - Increased Drug Resistance | Phase 1 / Phase 2 | Completed | University of Rochester | 27 | 2008-11-01 | 2012-11-06 |
| n-3 Polyunsaturated Fatty Acids in Obesity reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA), control - Adipose Tissue Inflammation, Morbid Obesity | Phase 2 | Completed | Medical University of Vienna | 55 | 2008-09-01 | 2016-03-16 |
| Lovaza's Effect on the Activation of Platelets Lovaza - Cardiovascular Disease, Bleeding | Phase 2 | Completed | Invitrox | 43 | 2007-09-01 | 2013-07-09 |
| Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Omacor - Chronic Heart Failure | Phase 2 / Phase 3 | Completed | Medical University of Vienna | 2005-09-01 | 2010-07-13 | |
| Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy omega-3 fatty acids, prednisone, Placebo - IgA Glomerulonephritis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 96 | 1997-11-01 | 2025-05-04 |
Hypertriglyceridemia (4) · Breast Neoplasms (3) · Cardiovascular Diseases (2) · Body Weight (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Type 2 (1) · Exocrine Pancreatic Insufficiency (1) · Glomerulonephritis, IGA (1) · HIV Infections (1) · Heart Diseases (1) · Hemorrhage (1) · Myocardial Infarction (1) · Myositis, Inclusion Body (1) · Obesity, Morbid (1) · Rare Diseases (1)
AstraZeneca (2) · Carol Fabian, MD (2) · Medical University of Vienna (2) · Babu Balagopal (1) · Invitrox (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis Pharmaceuticals (1) · Sanford Research (1) · University Hospitals Cleveland Medical Center (1) · University of Michigan Rogel Cancer Center (1) · University of Rochester (1) · Vanderbilt University (1) · Western Michigan University (1)
United States (12) · Austria (2) · Canada (1) · Denmark (1) · Hungary (1) · Latvia (1) · Poland (1) · Russia (1) · Slovakia (1) · Sweden (1)
Carol Fabian, MD (2) · Christopher C Cheatham, Ph.D. (1) · Grace McComsey, MD (1) · Gregory C Shearer, PhD (1) · Harvey J Murff, MD, MPH (1) · Lynn Henry, MD, PhD (1) · Mauricio Cohen, MD (1) · Robert C Block, MD, MPH (1) · Ronald Hogg (1) · Rudolf Berger, MD (1) · Samuel Gidding, MD (1) · Thomas M Stulnig, MD (1)
PMID 17699247, PMID 21570522, PMID 21621252, PMID 21870979, PMID 23034965, PMID 23312053, PMID 23372745, PMID 25393536, PMID 29802077, PMID 34291724, PMID 38299639
2014 (1), R01CA160938 (1), R01DK049368 (1)